November 2016

The largest recreational usage of cannabis is now the state of California. According to Gallup polls, public support for legalizing cannabis has reached 60%, its highest level in Gallup’s 47-year trend. The market for both recreational and medicinal cannabis is projected to grow to $22 billion by 2020 according to ArcView Market Research. GrowGeneration Corp. […]

by

GW Pharmaceuticals to Present at the 28th Annual Piper Jaffray Healthcare Conference on 29 November London, UK, 22 November 2016:GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that Justin Gover, GW’s Chief Executive […]

by

Editorial: Steve McIver, EditorAdvertising: Maureen Dwyer Liberti, Vice President, Group PublisherProduction: Dawn Flook, Director of Production ServicesCirculation: Jackie Ott, Circulation ManagerWebmaster: Webmaster … read more at: https://www.ptcommunity.com/wire/gw-pharmaceuticals-report-q4-and-year-end-financial-results-and-host-conference-call-5-december

by

Researchers at Toronto’s Hospital for Sick Children are poised to begin a clinical trial using cannabis extracts to treat children with severe epilepsy whose seizures can’t be controlled with existing medications. The trial is believed to be the first in Canada to test an oral preparation that contains both CBD and THC, compounds in marijuana […]

by

LONDON, Nov. 22, 2016 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that Justin Gover, GW’s Chief Executive Officer, will present at the 28th Annual Piper Jaffray Healthcare Conference on Tuesday, 29 […]

by

DEVON, Pa., Nov. 28, 2016 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that two posters relating to ZYN002, its patent-protected synthetic CBD gel,  have been selected for presentation at the upcoming 70th Annual Meeting of the American Epilepsy […]

by

LONDON, Nov. 22, 2016 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that Justin Gover, GW’s Chief Executive Officer, will present at the 28th Annual Piper Jaffray Healthcare Conference on Tuesday, 29 […]

by

LONDON, Nov. 22, 2016 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that Justin Gover, GW’s Chief Executive Officer, will present at the 28th Annual Piper Jaffray Healthcare Conference on Tuesday, 29 […]

by

Login to members area Don’t have registration yet ? “Create Account” If you have lost / forgotten your password click: “Lost Password” … read more at: https://mysunshinecoast.com.au/news/news-display/new-cannabis-trial-to-help-osteoarthritis-patients,46739

by

As Ohio grapples with ways to regulate the growth and distribution of medical marijuana, a University of Cincinnati doctor makes the case for an Food and Drug Administration-approved derivative.  Dr. Michael Privitera, the director of the UC Epilepsy Center and president of the American… read more at: http://www.newsrecord.org/news/uc-doctor-makes-case-for-medical-marijuana/article_9ee7ab74-aff3-11e6-bb10-ebcee23ec3dd.html

by